Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Olanzapine/Zyprexa Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 6, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

A Phase 1 Safety Study in Adults With Schizophrenia

NCT02804568
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 6, 2026, 10:55 AM EDT
Available No phase listed Expanded access

An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

NCT07744113
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia Disorder
Interventions
OLZ/SAM
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
10 Years to 17 Years
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

NCT00183625
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine, Risperidone
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 6, 2026, 10:55 AM EDT
Completed No phase listed Observational

Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

NCT03211897
View directory record Official record
Conditions
Agitation,Psychomotor
Interventions
Haloperidol Injection, Ziprasidone Injection, OLANZapine Injection, Midazolam injection
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
737 participants
Timeline
2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 6, 2026, 10:55 AM EDT
Terminated Not applicable Interventional

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

NCT00183612
View directory record Official record
Conditions
Bipolar Disorder, Psychotic Disorders
Interventions
Olanzapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

NCT00275301
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
olanzapine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

NCT03030417
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCT06107803
View directory record Official record
Conditions
Negative Symptoms in Schizophrenia
Interventions
Roluperidone 64 mg, Olanzapine 10 MG
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Hypochondriasis With CBT and/or SSRI

NCT00339079
View directory record Official record
Conditions
Hypochondriasis
Interventions
Fluoxetine, Cognitive Behavioral Therapy (CBT), Supportive Therapy, Placebo
Drug · Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 4 Interventional

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

NCT00287820
View directory record Official record
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Sustaining Remission of Psychotic Depression

NCT01427608
View directory record Official record
Conditions
Psychotic Depression
Interventions
Sertraline + Olanzapine, Sertraline + Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Worcester, Massachusetts • White Plains, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551
View directory record Official record
Conditions
Schizophrenia
Interventions
SCA-136 (200 mg), SCA-136 (400 mg), olanzapine (15 mg), placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Olanzapine for Nausea After Surgery

NCT02755116
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Jaime B Hyman
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCT00337662
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional

Pediatric Oncology Nutrition Intervention Trial

NCT06175273
View directory record Official record
Conditions
Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
Interventions
Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
Dietary Supplement · Drug · Other
Lead sponsor
Corey Hawes
Other
Eligibility
2 Years to 19 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 6, 2026, 10:55 AM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCT02873208
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 6, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 6, 2026, 10:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Pregnancy Registry for Psychiatric Medications

NCT01246765
View directory record Official record
Conditions
Pregnant Women, Psychotropic Drugs
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 6, 2026, 10:55 AM EDT